Latest Strategic Collaboration News

International Graphite's Springdale Project achieves over 99.95% purity in graphite purification tests coordinated by Marubeni, signaling strong potential for battery market supply.

Tamboran Resources has made significant strides in the Beetaloo Basin, completing two major wells and securing key infrastructure agreements, positioning itself for first gas production by mid-2026.

Predictive Discovery Limited has successfully completed a A$69.2 million strategic placement with key investors Lundin family and Zijin Mining Group, strengthening its financial position for future growth.

dorsaVi has secured a new commercial research project with renowned US surgeon Dr. Chirag Patel, leveraging its FDA-cleared wearable sensor technology and AI to enhance injury prevention and performance for elite athletes.

Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.

ANTAM has reported an all-time high in gold sales for FY24 alongside robust production in nickel and bauxite, underpinned by strategic partnerships and a strong sustainability agenda.

Mindax Limited progresses its Mid-West Shared Infrastructure Project and seeks development partners for the Mt Forrest Iron Project, while securing a significant R&D tax incentive refund.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.